香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司 2025年半年度報告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年8月22日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 上海昊海生物科技股份有限公司2025 年半年度报告 公司代码 ...

Company Overview - Shandong Buchang Pharmaceutical Co., Ltd. is located in Mudan District, Heze City, Shandong Province, established on May 10, 2001, and listed on November 18, 2016. The company specializes in the research, production, and sales of traditional Chinese medicine [1][2]. Stock Performance - As of August 22, Buchang Pharmaceutical's stock price decreased by 2.03%, trading at 18.78 CNY per share, with a total market capitalization of 19.805 billion CNY. The stock has increased by 18.86% year-to-date, with a 1.95% rise over the last five trading days, 4.04% over the last twenty days, and 13.68% over the last sixty days [1]. Financial Performance - For the period from January to March 2025, Buchang Pharmaceutical reported a revenue of 2.785 billion CNY, reflecting a year-on-year growth of 5.47%. The company has cumulatively distributed 7.537 billion CNY in dividends since its A-share listing, with 1.197 billion CNY distributed over the last three years [2]. Shareholder Information - As of March 31, 2025, the number of shareholders for Buchang Pharmaceutical was 59,500, a decrease of 0.44% from the previous period. The average number of circulating shares per shareholder increased by 0.44% to 18,587 shares [2]. Institutional Holdings - Among the top ten circulating shareholders as of March 31, 2025, Hong Kong Central Clearing Limited ranked as the ninth largest shareholder, holding 7.8596 million shares, a decrease of 576,000 shares from the previous period [2].

Group 1 - The latest stock price of Shuyupingmin is 13.07 yuan, an increase of 0.22 yuan from the previous trading day's closing price, representing a rise of 1.71% [1] - The stock opened at 12.85 yuan, reached a high of 13.15 yuan, and a low of 12.81 yuan, with a trading volume of 51,659 hands and a transaction amount of 0.67 billion yuan [1] - Shuyupingmin operates in several concept sectors including pharmaceutical commerce, Shandong sector, medical beauty, cold chain logistics, and Shenzhen Stock Connect [1] Group 2 - The company primarily engages in the retail chain operation of pharmaceuticals, mainly selling drugs, medical devices, and health products [1] - Recent regulations regarding self-service medicine dispensing machines have raised industry concerns, with a draft proposal allowing these machines to dispense prescription drugs and Class A non-prescription drugs, leading to worries about changes in the competitive landscape [1] - Industry insiders noted that the operational costs of self-service dispensing machines are significantly lower than traditional pharmacies, which may disrupt existing retail pharmacy business models [1] Group 3 - There are differing opinions on the regulation of self-service dispensing machines, with some advocating for strict limitations to Class B non-prescription drugs, while prescription drug sales should continue to adhere to existing regulatory requirements [1] - On August 19, 2025, Shuyupingmin experienced a net outflow of 2.1911 million yuan in main funds, accounting for 0.07% of its circulating market value [1] - Over the past five days, the net outflow of main funds reached 17.4921 million yuan, representing 0.55% of its circulating market value [1]

Company Overview - Wuzhou Medical's stock price closed at 42.06 yuan on August 8, 2025, down 0.78% from the previous trading day [1] - The opening price was 42.21 yuan, with a daily high of 43.24 yuan and a low of 41.61 yuan, resulting in a trading range of 3.85% [1] - The trading volume was 21,121 hands, with a transaction amount of 0.89 billion yuan and a turnover rate of 3.11% [1] Business Operations - Wuzhou Medical specializes in the research, development, production, and sales of medical devices, including medical consumables and equipment [1] - The company operates within the medical device industry and is also involved in related concepts such as medical aesthetics [1] Market Activity - On the morning of August 8, Wuzhou Medical experienced a rapid decline, with a drop of over 2% within 5 minutes [1] - By the end of the trading day, the net inflow of main funds was 2.773 million yuan, accounting for 0.1% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds was 1.8575 million yuan [1]

Core Viewpoint - The company, Shuyupingmin (301017.SZ), is currently not engaged in the medical beauty business and focuses on health and beauty products, including functional skincare and oral anti-aging products [1] Business Development - The company has established a Health and Beauty Division to enhance its product offerings [1] - Collaboration with the team of Academician Ling Peixue from China-Europe is aimed at developing a diversified product matrix for hyaluronic acid applications [1] - Partnership with the Evidence-Based Medical College to create a PDRN anti-aging product series [1] - Cooperation with a leading factory known for being the "global leader in recombinant collagen sales" to develop high-end skincare products, specifically molecular skin nectar [1] Customer-Centric Approach - The company emphasizes a customer-oriented strategy to continuously optimize its product categories [1] - The goal is to provide higher quality services to customers [1]

Core Viewpoint - The National Health Commission emphasizes the importance of distinguishing between medical and non-medical beauty services, highlighting the risks associated with non-professional practices in medical aesthetics [1][2][3] Group 1: Medical vs. Non-Medical Aesthetics - Medical aesthetics involves invasive techniques such as surgeries and injections aimed at repairing or reshaping appearance, while non-medical beauty services are non-invasive, like applying face masks [1] - Medical institutions must meet strict regulatory requirements to ensure safety and quality in medical aesthetic services, which can be verified through the National Health Commission's official website [1] Group 2: Risks of Non-Medical Aesthetic Practices - Increased risk of infection due to non-sterile environments and improper handling in non-medical settings, potentially leading to severe complications like sepsis [2] - Higher likelihood of adverse reactions from unregulated injection materials, which may cause serious allergic reactions or other health issues [2] - Greater risk of embolism from injections performed by non-professionals, which can result in severe consequences such as skin necrosis, blindness, or stroke [2][3] - Non-medical institutions lack effective emergency response measures, making it difficult to address complications like allergies or embolisms promptly [3]

Market Overview - The A-share market saw all major indices rise today, with the Shanghai Composite Index up by 0.43% closing at 3361.98 points, the Shenzhen Component Index up by 0.16% at 10057.17 points, the ChiNext Index up by 0.48% at 2002.70 points, and the Sci-Tech 50 Index up by 0.48% at 981.71 points [1][12] - Overall, 3390 stocks rose while 1782 stocks fell, with a total trading volume of 1141.4 billion yuan, an increase of 2.2 billion yuan compared to the previous trading day [1] Industry Performance - Among the Shenwan first-level industries, the sectors that saw gains included Beauty Care (up 3.86%), Textile and Apparel (up 2.53%), Comprehensive (up 2.02%), Banking (up 1.98%), and Agriculture, Forestry, Animal Husbandry, and Fishery (up 1.80%) [1][12] - The sectors that experienced declines included Household Appliances (down 2.10%), Steel (down 1.37%), Coal (down 0.84%), Building Materials (down 0.52%), and Environmental Protection (down 0.40%) [1][12] Concept Sectors - The top-performing concept sectors today included Gold and Jewelry, Medical Beauty, Dairy Industry, Gene Testing, CRO, Anti-Cancer, Rare Earth, Biological Vaccines, Innovative Drugs, and Medical Supplies Export [2][11] - Conversely, sectors such as Automotive Complete Vehicles, Wireless Charging, and Excavators experienced pullbacks [11]

Market Overview - The A-share market saw a majority of major indices decline today, with the Shanghai Composite Index down by 0.68% closing at 3380.82 points, the Shenzhen Component down by 1.62% at 10186.45 points, and the ChiNext Index down by 1.92% at 2043.25 points [1][14] - Overall, there were 1406 stocks that rose while 3856 stocks fell, with a total trading volume of 1152.4 billion yuan, a decrease of approximately 164.3 billion yuan compared to the previous trading day [1] Industry Performance - Among the Shenwan first-level industries, only the beauty care, coal, public utilities, and agriculture sectors saw gains, with increases of 3.68%, 0.42%, 0.12%, and 0.11% respectively [1][14] - The computer, communication, electronics, media, and defense industries experienced the largest declines, with drops of 2.97%, 2.45%, 2.12%, 1.93%, and 1.80% respectively [1] Sector Highlights - The top-performing concept sectors today included continuous boards, medical beauty, dairy, animal vaccines, rare earths, and food processing, among others [2][11] - Conversely, sectors such as financial technology, IDC, and stock trading software experienced pullbacks [11]

Market Overview - The A-share market showed mixed performance today, with the Shanghai Composite Index down by 0.05% closing at 3286.65 points, and the Shenzhen Component Index also down by 0.05% closing at 9849.80 points. The ChiNext Index fell by 0.13% to 1931.94 points. Overall, 3556 stocks rose while 1670 stocks fell, with a total trading volume of 10221 billion yuan, a decrease of approximately 34.2 billion yuan from the previous trading day [1][13]. Industry Performance - Among the Shenwan first-level industries, the leading sectors included Beauty Care, Machinery Equipment, Media, Light Industry Manufacturing, and Basic Chemicals, with respective gains of 2.60%, 1.44%, 1.27%, 1.04%, and 0.87%. Conversely, the sectors that experienced declines included Utilities, Comprehensive, Oil & Petrochemicals, Coal, and Social Services, with respective losses of 1.78%, 0.97%, 0.55%, 0.51%, and 0.47% [1][13]. Concept Sector Performance - The top-performing concept sectors today were Animal Vaccines, Marketing Communication, Medical Beauty, Auto Parts, Chemical Fibers, and Virtual Reality, among others. These sectors showed significant upward movement, while sectors like Electricity, Baijiu, and Insurance experienced pullbacks [2][11].

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Insights - The company reported a revenue of 3.026 billion yuan for 2024, representing a year-on-year growth of 5.45%, and a net profit attributable to shareholders of 1.958 billion yuan, which is a 5.33% increase year-on-year. A cash dividend of 38 yuan (including tax) is proposed for every 10 shares held [2][6]. Summary by Sections Financial Performance - In Q4 2024, the company experienced revenue pressure, achieving 650 million yuan, a year-on-year decline of 7%, and a net profit of 372 million yuan, down 15.5% year-on-year. The annual revenue breakdown for 2024 was 810 million, 850 million, 720 million, and 650 million yuan for Q1 to Q4, respectively, with changes of +28%, +2.35%, +1.1%, and -7% [12]. - For the entire year, the solution and gel products maintained stable growth, with revenue from solution products at 1.7 billion yuan (up 4.4% year-on-year) and gel products at 1.2 billion yuan (up 5% year-on-year). Direct sales channels generated approximately 2 billion yuan in sales (up 12.4%), while distribution channels saw a decline of 6% to about 1 billion yuan [12]. - The company maintained a gross margin of 95% for the year, with the gross margin for solution products narrowing by 0.72 percentage points and for gel products increasing by 0.49 percentage points. The R&D expense ratio rose to 10% [12]. Product Development and Market Outlook - The company has a rich pipeline of products in development, including a medical-grade polyvinyl alcohol gel for correcting chin retraction, which has received a Class III medical device registration certificate. Other products are in various stages of approval [12]. - The company plans to acquire a controlling stake in South Korea's REGEN, which is expected to enhance its regenerative materials product line and expand its global market presence [12]. - EPS forecasts for 2025, 2026, and 2027 are 7.12, 7.92, and 8.68 yuan, respectively, supporting the "Buy" rating [12].